Señales en vivo de PEB.NZ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 00:59):

Stats
Volumen de hoy	319 145
Volumen promedio	368 332
Capitalización de mercado	66.45M
EPS	NZD0 ( 2023-11-21 )
Próxima fecha de ganancias	( NZD0 ) 2024-05-23
Last Dividend	NZD0 ( N/A )
Next Dividend	NZD0 ( N/A )
P/E	-2.05
ATR14	NZD0 (0.00%)

Pacific Edge Limited Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pacific Edge Limited Finanzas

Annual	2023
Ingresos:	NZD19.62M
Beneficio Bruto:	NZD9.60M (48.96 %)
EPS:	NZD-0.0333

FY	2023
Ingresos:	NZD19.62M
Beneficio Bruto:	NZD9.60M (48.96 %)
EPS:	NZD-0.0333

FY	2022
Ingresos:	NZD11.45M
Beneficio Bruto:	NZD4.56M (39.85 %)
EPS:	NZD-0.0258

Financial Reports:

No articles found.

Pacific Edge Limited

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.